J Smolen

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint The definition and measurement of disease modification in inflammatory rheumatic diseases
    Daniel Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Rheum Dis Clin North Am 32:9-44, vii. 2006
  2. ncbi request reprint The assessment of disease activity in rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria
    Clin Exp Rheumatol 28:S18-27. 2010
  3. doi request reprint Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 73:6-16. 2014
  4. ncbi request reprint Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
    Josef S Smolen
    Division of Rheumatology, Department of Medicine Three, Medical University of Vienna, Vienna, Austria Second Department of Medicine, Hietzing Hospital, Vienna, Austria Electronic address
    Lancet 383:321-32. 2014
  5. pmc Value of self-performed joint counts in rheumatoid arthritis patients near remission
    Helga Radner
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringerguertel 18 20, Vienna, 1090, Austria
    Arthritis Res Ther 14:R61. 2012
  6. doi request reprint The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Nat Rev Rheumatol 8:235-43. 2012
  7. pmc Gait changes precede overt arthritis and strongly correlate with symptoms and histopathological events in pristane-induced arthritis
    Markus H Hoffmann
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 12:R41. 2010
  8. pmc The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
    Ruth Fritsch-Stork
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    Arthritis Res Ther 8:R118. 2006
  9. pmc The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function
    Bernhard M Kirsch
    Department of Internal Medicine III Clinical Division of Nephrology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 7:R694-703. 2005
  10. pmc The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 10:208. 2008

Collaborators

Detail Information

Publications108 found, 100 shown here

  1. ncbi request reprint The definition and measurement of disease modification in inflammatory rheumatic diseases
    Daniel Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Rheum Dis Clin North Am 32:9-44, vii. 2006
    ....
  2. ncbi request reprint The assessment of disease activity in rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria
    Clin Exp Rheumatol 28:S18-27. 2010
    ..The latest developments in the field are discussed and will help to identify patients who can benefit most from today's opportunities of pharmacotherapy, allowing optimization of patient care...
  3. doi request reprint Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 73:6-16. 2014
    ..Therapeutic targets have been defined for diseases like diabetes, hypertension or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just emerging for spondyloarthritis (SpA)...
  4. ncbi request reprint Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
    Josef S Smolen
    Division of Rheumatology, Department of Medicine Three, Medical University of Vienna, Vienna, Austria Second Department of Medicine, Hietzing Hospital, Vienna, Austria Electronic address
    Lancet 383:321-32. 2014
    ..The OPTIMA trial assessed different treatment adjustment strategies in patients with early rheumatoid arthritis attaining (or not) stable low disease activity with adalimumab plus methotrexate or methotrexate monotherapy...
  5. pmc Value of self-performed joint counts in rheumatoid arthritis patients near remission
    Helga Radner
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringerguertel 18 20, Vienna, 1090, Austria
    Arthritis Res Ther 14:R61. 2012
    ..To determine the validity and reliability of patients' self-performed joint counts compared to joint counts by professional assessors in rheumatoid arthritis (RA) patients in different disease activity states...
  6. doi request reprint The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Nat Rev Rheumatol 8:235-43. 2012
    ..This article discusses these disparities and presents hypotheses as to whether clinical trial data can be used to determine at which point a biologic agent might interfere with the pathogenetic cascade in RA...
  7. pmc Gait changes precede overt arthritis and strongly correlate with symptoms and histopathological events in pristane-induced arthritis
    Markus H Hoffmann
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 12:R41. 2010
    ..To investigate this issue a detailed analysis of the pathologic changes occurring during the prodromal and early stages of PIA was performed...
  8. pmc The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
    Ruth Fritsch-Stork
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    Arthritis Res Ther 8:R118. 2006
    ..Taken together, the pronounced peripheral T cell reactivity to hnRNP-A2 observed in the majority of SLE patients and the distinct phenotype of patient-derived CD8+ TCCs suggest a role for these T cells in the pathogenesis of SLE...
  9. pmc The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function
    Bernhard M Kirsch
    Department of Internal Medicine III Clinical Division of Nephrology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 7:R694-703. 2005
    ..These data indicate that interference with several aspects of DC function could significantly contribute to the beneficial effects of leflunomide in inflammatory diseases, including RA...
  10. pmc The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 10:208. 2008
    ..The analysis suggests the search for better markers to predict outcomes and therapeutic responsiveness in rheumatoid arthritis needs to be intensified...
  11. doi request reprint Monitoring rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Austria
    Curr Opin Rheumatol 23:252-8. 2011
    ..Here we review the most recent insights related to monitoring of rheumatoid arthritis...
  12. doi request reprint Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Lancet 371:987-97. 2008
    ..Our aim was to assess the therapeutic effects of blocking interleukin 6 by inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis...
  13. pmc Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
    J Smolen
    Department of Internal Medicine III, Medical University of Vienna and 2nd Department of Medicine, Hietzing Hospital, Austria
    Ann Rheum Dis 68:797-804. 2009
    ..Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor...
  14. doi request reprint Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Nat Clin Pract Rheumatol 4:296-7. 2008
  15. doi request reprint Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
    Josef S Smolen
    Medical University of Vienna and Hietzing Hospital, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria
    Lancet 374:210-21. 2009
    ..We assess the efficacy and safety of the TNFalpha inhibitor golimumab in patients with active rheumatoid arthritis who had previously received one or more TNFalpha inhibitors...
  16. pmc Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo
    Birgit Görtz
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria
    Arthritis Res Ther 7:R1140-7. 2005
    ....
  17. ncbi request reprint Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study
    Martin Aringer
    Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 50:3161-9. 2004
    ....
  18. ncbi request reprint Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin
    Kurt Redlich
    University of Vienna, Vienna, Austria
    Arthritis Rheum 46:785-92. 2002
    ..To study the effects of osteoclast-targeted therapies, such as osteoprotegerin (OPG) and pamidronate, on joint inflammation and bone destruction using a tumor necrosis factor alpha (TNF alpha)-transgenic mouse model...
  19. ncbi request reprint Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis
    Petra Herrak
    University of Vienna, Vienna, Austria
    Arthritis Rheum 50:2327-37. 2004
    ..Zoledronic acid (ZA) is one of the most potent agents for blocking osteoclast function. We therefore investigated whether ZA can inhibit the bone loss associated with chronic inflammatory conditions...
  20. ncbi request reprint Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis
    Beate Rüger
    University of Vienna, Vienna, Austria
    Arthritis Rheum 50:2157-66. 2004
    ..To find evidence for the presence of endothelial precursor cells, which can induce new vessel formation, in the synovial tissue of patients with rheumatoid arthritis (RA) and osteoarthritis (OA)...
  21. pmc Osteoclasts are essential for TNF-alpha-mediated joint destruction
    Kurt Redlich
    Department of Internal Medicine III, Division of Rheumatology, University of Vienna, Vienna, Austria
    J Clin Invest 110:1419-27. 2002
    ..Therefore, in addition to the use of anti-inflammatory therapies, osteoclast inhibition could be beneficial for the treatment of rheumatoid arthritis...
  22. ncbi request reprint Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction
    Jochen Zwerina
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 54:463-72. 2006
    ..Mice overexpressing TNF were treated with 2 different inhibitors of p38 MAPK, and the effect of this treatment on joint inflammation and structural damage was assessed...
  23. pmc Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis
    Kurt Redlich
    Department of Internal Medicine III, University of Vienna, Vienna, Austria
    Am J Pathol 164:543-55. 2004
    ....
  24. doi request reprint Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients
    Martin Aringer
    Department of Medicine III, Division of Rheumatology, University Clinical Center Carl Gustav Carus at the Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Rheumatology (Oxford) 48:1451-4. 2009
    ..To follow-up on all available infliximab-treated SLE patients for safety and long-term efficacy in order to extract information that is useful for planning appropriate controlled trials with infliximab in SLE...
  25. ncbi request reprint The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis
    D Aletaha
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Exp Rheumatol 23:S100-8. 2005
    ....
  26. doi request reprint Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis
    Stephan Blüml
    Medical University of Vienna and Center of Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
    Arthritis Rheum 62:1608-19. 2010
    ....
  27. pmc CD44 is a determinant of inflammatory bone loss
    Silvia Hayer
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, A 1090 Vienna, Austria
    J Exp Med 201:903-14. 2005
    ..These data identify CD44 as a critical inhibitor of TNF-driven joint destruction and inflammatory bone loss...
  28. doi request reprint Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:1058-64. 2010
    ..Joint damage is an important outcome in trials of rheumatoid arthritis (RA), usually assessed by Total Sharp Score (TSS). It is currently unknown how it translates numerically into disability by the Health Assessment Questionnaire (HAQ)...
  29. ncbi request reprint Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
    Daniel Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 56:3226-35. 2007
    ..To assess whether disease activity levels at treatment initiation or during the first 3 months of therapy predict disease activity at 1 year after treatment initiation...
  30. ncbi request reprint Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption
    Jochen Zwerina
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    FASEB J 19:2011-3. 2005
    ..In summary, these data indicate that HO-1 negatively regulates osteoclastogenesis, leading to a positive net balance of bone...
  31. ncbi request reprint Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice
    Georg Schett
    Department of Internal Medicine III, Division of Rheumatology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Arthritis Rheum 48:2042-51. 2003
    ..To investigate the role of tumor necrosis factor (TNF) in systemic bone loss of chronic inflammatory conditions, such as rheumatoid arthritis (RA), and to address the therapeutic potential of osteoclast blockade...
  32. ncbi request reprint Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Curr Rheumatol Rep 5:409-12. 2003
  33. ncbi request reprint The burden of rheumatoid arthritis and access to treatment: a medical overview
    J Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Eur J Health Econ 8:S39-47. 2008
    ..Therapeutic outcome can be predicted by clinical means...
  34. ncbi request reprint Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease
    Klaus P Machold
    Department of Rheumatology, University of Vienna, Vienna, Austria
    J Rheumatol 29:2278-87. 2002
    ..To describe clinical and radiological findings in patients with very early arthritis (< 3 months of symptoms) during one year of observation...
  35. doi request reprint Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis
    Monika Schoels
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 69:1441-7. 2010
    ..Therefore, the reliability and validity of DAREA (for 'Disease Activity index for REactive Arthritis'), which was originally developed for reactive arthritis and employs a 66/68 joint count, was tested in patients with PsA...
  36. doi request reprint Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis
    Valerie P Nell-Duxneuner
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:546-9. 2010
    ..Specific composite indices assessing disease activity in psoriatic arthritis (PsA) have not yet been sufficiently validated. The objective of this study was to identify instruments best reflecting disease activity in PsA...
  37. ncbi request reprint Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:702-10. 2006
    ..To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX...
  38. ncbi request reprint Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation
    Johannes Grisar
    Department of Internal Medicine III, University of Vienna, Austria
    J Rheumatol 29:1430-6. 2002
    ..To test if markers of bone metabolism are altered in patients with seronegative spondyloarthropathies (SSpA)...
  39. ncbi request reprint Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus
    Martin Aringer
    University Clinical Center Carl Gustav Carus, Technical University of Dresden, Division of Rheumatology, Department of Medicine III, Fetscherstrasse 74, 01307 Dresden, Germany
    Expert Opin Drug Saf 7:411-9. 2008
    ..There is still unmet medical need in the therapy of severe organ manifestations of patients with systemic lupus erythematosus (SLE). Therapeutic agents targeting pro-inflammatory cytokines may be an interesting option...
  40. ncbi request reprint Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice
    G Schett
    Department of Internal Medicine III, University of Vienna, Austria
    Arthritis Rheum 44:2888-98. 2001
    ....
  41. pmc The stressed synovium
    G Schett
    Department of Internal Medicine III, University of Vienna, Wahringer Gurtel 18 20, A 1180 Vienna, Austria
    Arthritis Res 3:80-6. 2001
    ..Stress signalling pathways are therefore new and promising targets of future anti-rheumatic therapies...
  42. doi request reprint Life stories of people with rheumatoid arthritis who retired early: how gender and other contextual factors shaped their everyday activities, including paid work
    T A Stamm
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Musculoskeletal Care 8:78-86. 2010
    ..The aim of the present study was to explore how contextual factors affect the everyday activities of women and men with rheumatoid arthritis (RA), as evident in their life stories...
  43. doi request reprint [Rheumatoid arthritis. Target outcome for treatment]
    D Aletaha
    Klinische Abteilung für Rheumatologie, Klinik für Innere Medizin 3, Medizinische Universität Wien, Wahringer Gurtel 18 20, 1090, Wien, Osterreich
    Z Rheumatol 68:10-5. 2009
    ..Standardised intensive therapeutic strategies and algorithms should form the basis for the administration of anti-rheumatic medication...
  44. ncbi request reprint [Systemic lupus erythematosus--activity and outcome]
    M Aringer
    Klinische Abt für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien
    Z Rheumatol 65:103-6, 108-9. 2006
    ..The combination of shorter studies for defining hopeful strategies followed by long definitive studies, appears to be the best option at present...
  45. ncbi request reprint [Activity-score based therapy in rheumatoid arthritis]
    K Machold
    Klinische Abt für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien
    Z Rheumatol 65:124, 126-30. 2006
    ..This review presents evidence for the benefits of the application disease activity scores in clinical routine...
  46. ncbi request reprint [Clinical outcome measures in hand- and finger joint osteoarthritis from the patient perspective]
    T Stamm
    Abt für Rheumatologie, Klinik fur Innere Medizin III, Medizinische Universität Wien
    Z Rheumatol 65:139-43. 2006
    ..Some instruments lack reliability because standardized protocols for measurement have not yet been developed...
  47. ncbi request reprint [Measuring disease activity for rheumatoid arthritis]
    D Aletaha
    Klinische Abt für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien
    Z Rheumatol 65:93-6, 98-102. 2006
    ..This will further improve our ability to care for patients with RA consequently...
  48. ncbi request reprint The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis
    Markus H Hoffmann
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    J Immunol 179:7568-76. 2007
    ..Taken together, these data suggest hnRNP-A2 to be among the primary inducers of autoimmunity in PIA. Therefore, this Ag might play a pivotal role in the pathogenesis of PIA and possibly also human RA...
  49. ncbi request reprint Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status
    Tanja A Stamm
    Vienna Medical University, Vienna, Austria
    Arthritis Rheum 57:1287-95. 2007
    ..To explore the array of concepts important to patients with chronic systemic lupus erythematosus (SLE) and to compare these with instruments assessing disease activity, damage, and health status...
  50. doi request reprint Differentially regulated expression of growth differentiation factor 5 and bone morphogenetic protein 7 in articular cartilage and synovium in murine chronic arthritis: potential importance for cartilage breakdown and synovial hypertrophy
    Klaus Bobacz
    University of Vienna, Vienna, Austria
    Arthritis Rheum 58:109-18. 2008
    ....
  51. pmc Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries
    Tanja A Stamm
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Ann Rheum Dis 70:1074-9. 2011
    ....
  52. pmc EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:964-75. 2010
    ....
  53. ncbi request reprint Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008
    Monika Schoels
    2nd Department of Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 69:575-8. 2010
    ..The importance of tight control and early treatment, rapidly altered if goals are not achieved, is supported by evidence. However, it is unknown to what extent these insights are accepted by practitioners in clinical practice...
  54. doi request reprint Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction
    Daniel Aletaha
    Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Ann Rheum Dis 70:733-9. 2011
    ..It is currently unclear to which extent these components affect irreversible functional disability. The aim of the present work was to determine these contributions...
  55. doi request reprint Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis
    Helga Radner
    Department of Internal Medicine 3, Medical University Vienna, 1090 Vienna, Austria
    Rheumatology (Oxford) 50:381-8. 2011
    ..In this study, we investigated the impact of comorbidities on individual activities of daily living, and other aspects of quality of live in patients with RA...
  56. doi request reprint The importance of reporting disease activity states in rheumatoid arthritis clinical trials
    Daniel Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 58:2622-31. 2008
    ..g., American College of Rheumatology [ACR] responder status) with the value of evaluating absolute disease activity states (e.g., remission)...
  57. ncbi request reprint The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I
    Julia Funovits
    Division of Rheumatology, Medical University Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:1589-95. 2010
    ....
  58. pmc JNK1 is not essential for TNF-mediated joint disease
    Marcus Koller
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Austria
    Arthritis Res Ther 7:R166-73. 2005
    ..Thus, JNK1 activation does not seem to be essential for TNF-mediated arthritis...
  59. ncbi request reprint The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis
    Klaus P Machold
    Medical University of Vienna, Vienna A 1090, Austria
    Ann Rheum Dis 69:495-502. 2010
    ....
  60. doi request reprint The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheum Dis Clin North Am 35:759-72, viii. 2009
    ..Moreover, remission criteria of CDAI and SDAI are currently the most stringent...
  61. doi request reprint Impact of comorbidity on physical function in patients with rheumatoid arthritis
    Helga Radner
    Division of Rheumatology, Department of Internal Medicine 3, Medical University Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Ann Rheum Dis 69:536-41. 2010
    ..Physical disability is a main outcome in rheumatoid arthritis (RA) which tends to increase with comorbidities. However, the extent to which comorbidities contribute to the multifactorial process of disability has not been investigated...
  62. doi request reprint Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients
    Marcus D Köller
    Department of Rheumatology Internal Medicine III, General Hospital Medical University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 48:1575-80. 2009
    ..To compare the efficacy of MTX and MTX+TNF inhibitors (TNFis) in elderly patients with RA with that in patients of younger age...
  63. pmc Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
    Theresa Kapral
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Arthritis Res Ther 9:R72. 2007
    ..However, reduced joint counts are appropriate and valid tools for formal disease activity assessment, such as done in composite indices...
  64. pmc Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy
    Johannes Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 66:1284-8. 2007
    ....
  65. ncbi request reprint The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy
    Josef S Smolen
    Division of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    J Rheumatol Suppl 71:13-20. 2004
    ..Moreover, to ensure good tolerability and compliance in patients receiving a loading dose, information and adequate support should be provided throughout treatment...
  66. pmc Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis
    Jochen Zwerina
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 8:R22. 2006
    ..These data indicate that bone resorption dominates at skeletal sites close to synovial inflammatory tissue, whereas bone formation is induced at more distant sites attempting to counter-regulate bone resorption...
  67. ncbi request reprint New insights in the mechanism of bone loss in arthritis
    Georg Schett
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria
    Curr Pharm Des 11:3039-49. 2005
    ..In contrast, chronic forms of arthritis, such as psoriatic arthritis or rheumatoid arthritis (RA) are usually destructive and lead to alteration of joint structure and functional impairment...
  68. ncbi request reprint Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states
    Daniel Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 52:2625-36. 2005
    ..We aimed to reevaluate or to define such criteria for the Disease Activity Score in 28 joints (DAS28) and the Simplified Disease Activity Index (SDAI)...
  69. ncbi request reprint Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease
    Klaus P Machold
    Department of Internal Medicine 3, Vienna University, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Expert Opin Biol Ther 3:351-60. 2003
    ..Moreover, radiographic progression is significantly inhibited and quality of life improved. This article summarises the available information...
  70. ncbi request reprint Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for Rheumatoid Arthritis from the patient perspective: a qualitative study
    Tanja A Stamm
    Division of Rheumatology, Department of Internal Medicine III, Vienna Medical University, Vienna, Austria
    Arthritis Rheum 53:431-9. 2005
    ..To validate the International Classification of Functioning, Disability and Health (ICF) Comprehensive Core Set for Rheumatoid Arthritis (RA) from the patient perspective...
  71. pmc Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature
    Georg Schett
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Microbiol 43:2537-41. 2005
    ..We review the literature of articular listeriosis and discuss the role of tumor necrosis factor blockade in precipitating listeriosis...
  72. ncbi request reprint Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis
    Johannes Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Circulation 111:204-11. 2005
    ..Because the quantity of endothelial progenitor cells (EPCs) in the peripheral blood is correlated inversely with cardiovascular risk, we studied whether such abnormalities could also be observed in patients with RA...
  73. ncbi request reprint Content comparison of occupation-based instruments in adult rheumatology and musculoskeletal rehabilitation based on the International Classification of Functioning, Disability and Health
    Tanja A Stamm
    Vienna Medical University, Vienna, Austria
    Arthritis Rheum 51:917-24. 2004
    ....
  74. pmc Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?
    Klaus P Machold
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:211. 2006
    ..Assessment of risks in the individual patient, allowing individual 'tailoring' of the initial treatment, would be desirable...
  75. ncbi request reprint The health assessment questionnaire in routine clinical practice
    Daniel Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Nat Clin Pract Rheumatol 3:122-3. 2007
  76. pmc The public neglect of rheumatic diseases: insights from analyses of attendees in a musculoskeletal disease awareness activity
    Klaus P Machold
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 66:697-9. 2007
    ..To obtain data on the care received by individuals counselled during a public health awareness campaign on painful musculoskeletal conditions (MSC)...
  77. ncbi request reprint Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus
    Martin Aringer
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 56:274-9. 2007
    ..To analyze changes in autoantibodies occurring in patients with systemic lupus erythematosus (SLE) treated with 4 infusions of the chimeric anti-tumor necrosis factor alpha (TNFalpha) antibody infliximab...
  78. ncbi request reprint Challenges of predicting treatment response in patients with rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Nat Clin Pract Rheumatol 1:62-3. 2005
  79. ncbi request reprint Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning
    Tanja A Stamm
    Department of Internal Medicine III, Division of Rheumatology, Vienna Medical University, Vienna, Austria
    Arthritis Rheum 57:487-94. 2007
    ..To explore whether the concepts important to patients with psoriatic arthritis (PsA) are covered by self-report instruments assessing functioning...
  80. ncbi request reprint Mechanisms of Disease: the link between RANKL and arthritic bone disease
    Georg Schett
    Medical University of Vienna, Austria
    Nat Clin Pract Rheumatol 1:47-54. 2005
    ..Therefore, inhibition of RANKL is regarded as a promising future strategy for inhibiting inflammatory bone loss in patients with chronic inflammatory arthritis...
  81. pmc The role of tumor necrosis factor-alpha in systemic lupus erythematosus
    Martin Aringer
    Division of Rheumatology, Department of Medicine III, University Clinical Center Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Arthritis Res Ther 10:202. 2008
    ..At the same time, open-label data suggest that TNF blockade suppresses inflammatory manifestations of SLE, and long-term benefit was seen in patients with lupus nephritis. A controlled clinical trial is under way...
  82. ncbi request reprint Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosus
    G Schett
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna Medical School, Vienna, Austria
    Rheumatology (Oxford) 40:424-31. 2001
    ..Anti-erythropoietin antibodies are frequently present in SLE and interfere with the measurement of serum erythropoietin level. However, these antibodies are not associated with increased severity of SLE-associated anaemia...
  83. doi request reprint Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE)
    Michael Bonelli
    Division of Rheumatology, Internal Medicine III, General Hospital of Vienna, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Wien, Austria
    Int Immunol 20:861-8. 2008
    ..Our data describe quantitative and qualitative defects of Treg in SLE patients. These deficiencies might contribute to the breakdown of self-tolerance and the development of the autoimmune response in SLE patients...
  84. ncbi request reprint Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis
    Ruth Fritsch
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria
    J Immunol 169:1068-76. 2002
    ..Taken together, the presence of autoreactive Th1-like cells in RA patients in conjunction with synovial overexpression of A2/RA33 may indicate potential involvement of this autoantigen in the pathogenesis of RA...
  85. pmc Treating rheumatoid arthritis to target: recommendations of an international task force
    Josef S Smolen
    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:631-7. 2010
    ..Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA)...
  86. pmc Obstruction of the pulmonary artery by granulomatous vasculitis: a clinical, morphological, and immunological analysis
    G Schett
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Ann Rheum Dis 61:463-7. 2002
  87. doi request reprint A1.80 Alterations in gait profile and bone marrow inflammation before the onset of collagen-induced arthritis
    K Sinn
    Medical University of Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria
    Ann Rheum Dis 73:A35. 2014
    ..Chronic inflammation of joints ulimatively leads to bone and cartilage damage resulting in functional impairment or even complete disabilities of joints in RA patients...
  88. ncbi request reprint Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report
    M Brunner
    Internal Medicine I, University of Vienna Medical School, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Rheum 46:1580-4. 2002
    ..Her pulmonary function has returned to normal. Although a longer followup is required for assessment of the durability of response, the patient's course indicates that ASCT may be a way to reinduce tolerance in patients with SLE...
  89. ncbi request reprint Is pro-matrix metalloproteinase-3 a marker for posttraumatic cartilage degradation?
    K Bobacz
    Department of Internal Medicine III, Division of Rheumatology, University of Vienna, Vienna, Austria
    Osteoarthritis Cartilage 11:665-72. 2003
    ..In this study we investigated the significance of pro-matrixmetalloproteinase-3 (proMMP-3) for this purpose...
  90. doi request reprint Patient perspective of hand osteoarthritis in relation to concepts covered by instruments measuring functioning: a qualitative European multicentre study
    T Stamm
    Vienna Medical University, Department of Internal Medicine III, Division of Rheumatology, Wahringer Gurtel 18 20, Vienna A 1090, Austria
    Ann Rheum Dis 68:1453-60. 2009
    ..To explore whether the concepts important to patients with hand osteoarthritis (OA) are covered by the most commonly used instruments measuring functioning...
  91. ncbi request reprint Clinical study on the effect of infrared radiation of a tiled stove on patients with hand osteoarthritis
    L Stange-Rezende
    Vienna Medical University, Department of Internal Medicine III, Division of Rheumatology, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Scand J Rheumatol 35:476-80. 2006
    ..To explore the effect of infrared radiation of a tiled stove on patients with hand osteoarthritis (OA)...
  92. ncbi request reprint Pharmacological management of early rheumatoid arthritis--does combination therapy improve outcomes?
    Maxime Dougados
    Hĵpital Cochin, Department of Rheumatology, Paris, France
    J Rheumatol Suppl 66:20-6. 2002
    ..Collectively, these data are beginning to shed light on how to best treat early RA, suggesting that DMARD work best when given very early...
  93. ncbi request reprint Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis
    Sudha Visvanathan
    Centocor, Inc, Malvern, Pennsylvania, USA
    J Rheumatol 34:1465-74. 2007
    ....
  94. ncbi request reprint Overexpression of tumor necrosis factor causes bilateral sacroiliitis
    Kurt Redlich
    University of Vienna Vienna, Austria
    Arthritis Rheum 50:1001-5. 2004
  95. ncbi request reprint Objectives and strategies for rheumatoid arthritis therapy: yesterday vs. today
    Josef S Smolen
    Department of Rheumatology, Vienna General Hospital, University of Vienna, Vienna, Austria
    Drugs Today (Barc) 39:3-8. 2003
    ..In addition, the efficacy of this treatment design can only be achieved if disease activity is monitored...
  96. ncbi request reprint The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care
    Josef S Smolen
    Department of Rheumatology, Internal Medicine III, Vienna General Hospital, University of Vienna, Wolkersbergenstrasse 1, Vienna A 1130, Austria
    Curr Rheumatol Rep 5:336-40. 2003
  97. ncbi request reprint Lefunomide in combination therapy
    Joachim R Kalden
    Department of Internal Medicine III, Universitaet Erlangen Nuremberg, Erlangen, Germany
    J Rheumatol Suppl 71:25-30. 2004
    ..The Expert Panel concluded that combination therapy with leflunomide has a place in the treatment of RA. Caution is advised, however, when using combination treatments and, therefore, the patient's safety should be carefully monitored...
  98. ncbi request reprint Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
    E William St Clair
    Duke University Medical Center, Durham, North Carolina, USA
    Arthritis Rheum 50:3432-43. 2004
    ....
  99. ncbi request reprint Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
    Christian E Antoni
    Clinical Immunology, Schering Plough Corporation, Kenilworth, New Jersey 07033 0530, USA
    J Rheumatol 35:869-76. 2008
    ..To investigate longterm efficacy/safety of infliximab over 2 years in patients with active psoriatic arthritis (PsA)...
  100. pmc Interleukin-6: a new therapeutic target
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:S5. 2006
    ..Here, we review recent phase II trials of tocilizumab, a humanized anti-IL-6 receptor antibody that achieves a significant therapeutic response rate...
  101. ncbi request reprint Infliximab treatment maintains employability in patients with early rheumatoid arthritis
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:716-22. 2006
    ..To evaluate the impact of infliximab therapy on the employment status of patients with early rheumatoid arthritis (RA)...